NEW YORK (GenomeWeb) – Veracyte today announced that it has entered into a definitive agreement to sell approximately $40 million in stock in a private placement.

Under the terms of the agreement, the investors will purchase 4,907,975 shares of common stock at $8.15 per share, the closing price on April 22, 2015. Investors include Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners, and venBio.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.